Lina Albitar

452 total citations
12 papers, 374 citations indexed

About

Lina Albitar is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lina Albitar has authored 12 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lina Albitar's work include HER2/EGFR in Cancer Research (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Lina Albitar is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Lina Albitar collaborates with scholars based in United States, China and Syria. Lina Albitar's co-authors include Kimberly K. Leslie, Gavin Pickett, Samuel C. Mok, Mark B. Carter, Ross S. Berkowitz, William R. Welch, Goli Samimi, Donghai Dai, Michael J. Birrer and Richard G. LeBaron and has published in prestigious journals such as Cancer Research, Molecular Cancer and Molecular Cancer Therapeutics.

In The Last Decade

Lina Albitar

12 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lina Albitar United States 10 204 117 99 69 59 12 374
Yousuke Ueoka Japan 13 273 1.3× 188 1.6× 78 0.8× 56 0.8× 61 1.0× 19 503
Shannon E. Muir United States 6 215 1.1× 155 1.3× 76 0.8× 44 0.6× 36 0.6× 7 399
Sundersingh Shirley India 8 246 1.2× 116 1.0× 115 1.2× 32 0.5× 15 0.3× 14 430
J. Schwarz Germany 7 165 0.8× 61 0.5× 71 0.7× 30 0.4× 20 0.3× 9 308
Jun Naniwa Japan 13 223 1.1× 114 1.0× 53 0.5× 75 1.1× 18 0.3× 19 399
Naoki Ogane Japan 14 205 1.0× 116 1.0× 160 1.6× 72 1.0× 18 0.3× 26 437
Jennifer Veneris United States 11 174 0.9× 250 2.1× 73 0.7× 106 1.5× 49 0.8× 33 492
Raquel Ramírez‐Moreno Spain 12 170 0.8× 225 1.9× 209 2.1× 63 0.9× 80 1.4× 23 499
Jennifer R. Ribeiro United States 13 190 0.9× 158 1.4× 146 1.5× 27 0.4× 35 0.6× 42 482
Rui Gou China 16 367 1.8× 120 1.0× 248 2.5× 33 0.5× 22 0.4× 28 547

Countries citing papers authored by Lina Albitar

Since Specialization
Citations

This map shows the geographic impact of Lina Albitar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lina Albitar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lina Albitar more than expected).

Fields of papers citing papers by Lina Albitar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lina Albitar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lina Albitar. The network helps show where Lina Albitar may publish in the future.

Co-authorship network of co-authors of Lina Albitar

This figure shows the co-authorship network connecting the top 25 collaborators of Lina Albitar. A scholar is included among the top collaborators of Lina Albitar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lina Albitar. Lina Albitar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Albitar, Lina, et al.. (2021). Pharmacogenetics: Knowledge assessment amongst Syrian pharmacists and physicians. BMC Health Services Research. 21(1). 1031–1031. 13 indexed citations
2.
Albitar, Lina, et al.. (2016). Rare isolated primary peritoneal hydatid cysts: A case report from Syria. Qatar medical journal. 2016(2). 13–13. 4 indexed citations
3.
Meng, Xiangbing, Elizabeth A. Kosmacek, Shujie Yang, et al.. (2012). Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecologic Oncology. 128(3). 461–469. 30 indexed citations
4.
5.
Albitar, Lina, et al.. (2010). EGFR isoforms and gene regulation in human endometrial cancer cells. Molecular Cancer. 9(1). 166–166. 44 indexed citations
6.
Ghosh, Sue, Lina Albitar, Richard G. LeBaron, et al.. (2010). Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecologic Oncology. 119(1). 114–120. 67 indexed citations
7.
Aponte, Margarita, Wei Jiang, Dale Edwards, et al.. (2008). Activation of Platelet-Activating Factor Receptor and Pleiotropic Effects on Tyrosine Phospho-EGFR/Src/FAK/Paxillin in Ovarian Cancer. Cancer Research. 68(14). 5839–5848. 67 indexed citations
8.
Albitar, Lina, et al.. (2007). Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecologic Oncology. 106(1). 52–64. 54 indexed citations
9.
Albitar, Lina, et al.. (2007). Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer. Gynecologic Oncology. 106(1). 94–104. 31 indexed citations
10.
Dai, Donghai, et al.. (2005). A therapeutic model for advanced endometrial cancer: Systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Molecular Cancer Therapeutics. 4(1). 169–175. 26 indexed citations
11.
Leslie, Kimberly K., et al.. (2005). Tyrosine kinase inhibitors in endometrial cancer. International Journal of Gynecological Cancer. 15(2). 409–411. 13 indexed citations
12.
Albitar, Lina, et al.. (2005). Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Molecular Cancer Therapeutics. 4(12). 1891–1899. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026